Our commitment to innovative technology in Rare Disease

At UCB, we believe in the power of partnerships and using data and technology with purpose to solve some of the most complex challenges in healthcare. To that end, we are excited to collaborate with doc.ai, a leading artificial intelligence (AI) platform that specializes in the capture of real-world data. The goal of this collaboration is to increase our understanding of the nuances and complexities of myasthenia gravis (MG) so that we can ultimately develop better treatments for patients.

Together, doc.ai and UCB will launch an at-home digital health trial app designed to detect facial muscle changes and vocal muscle weakness in people with MG and build an AI model that can predict symptom patterns and flares. Participants will document their symptoms through a daily survey as well as audio and video recordings twice a week and track other health information, such as exercise and diet, to provide an accurate picture of their health. Ultimately, this AI technology may help people with MG track their disease progression and make informed decisions on when to push themselves and when to rest.

MG is a rare, autoimmune, neuromuscular condition where the body’s immune system mistakenly targets the connection between the nerves and the muscles. The most common symptoms of MG are muscle weakness and fatigue; however, symptoms can vary greatly, which can cause profound unpredictability. The lack of understanding surrounding the triggers for intermittent worsening of symptoms can significantly affect the disease experience. Improving understanding about the day-to-day experience of living with MG is urgently needed. Only then can we fully appreciate the impact of uncontrolled MG on patients and accelerate better outcomes.

UCB’s research collaboration with doc.ai is the first of its kind. By leveraging the power of doc.ai’s cutting-edge technology in combination with our expertise in neurology and rare disease, we hope to optimize care for people with MG.